Updates are available Correction dated 2025-02-05
Click to view Correction: https://doi.org/10.1038/s41598-025-88934-0
-
Authors
Sato, Shinri
Ogawa, Yoko
Asai, Kazuki
Shimizu, Eisuke
Shimizu, Shota
Taniguchi, Hiroko
Okazaki, Takahiro
Shimmura, Shigeto
Negishi, Kazuno
Hirayama, Masatoshi
-
Funding
Funding for this research was provided by:
Japanese Ministry of Education, Science, Sports, Culture, and Technology (22K16982)
- License Information
-
More Information
Article History
Received: 11 April 2024
Accepted: 23 December 2024
First Online: 2 January 2025
Change Date: 5 February 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-025-88934-0
Declarations
:
: S. Sato and E. S. received delgocitinib, 0.5% delgocitinib ointment and solvent vehicle ointments from JT, and the preparation method of delgocitinib eye drops was provided by ROHTO Pharmaceutical Co., Ltd. S. Shimizu, H. T., K. A., T.O., M. H., S. Shimmura, K. N., and Y. O. declare no financial or nonfinancial conflicts of interest associated with this manuscript.
